Minerva Biotechnologies Corp. has raised about $4.6 million of planned $5.9 million equity offering, according to a filing with the U.S. Securities and Exchange Commission. In addition to equity, the regulatory filing notes that the Waltham biotech firm is offering warrants that could amount to $1.13 million more.
Minerva focuses on both nanotechnology and stem cell therapeutics. In 2008, the company, alongside the University of California at Santa Barbara, announced they may have found a “pivotal switch” in stem cell differrentiation. According to researchers, the discovery could lead to big advancements in stem cell treatments and further the understanding of how they operate.